The Adrenal Gland Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Adrenal Gland Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Adrenal Gland Cancer. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Adrenal Gland Cancer and features dormant and discontinued products.
GlobalData tracks 47 drugs in development for Adrenal Gland Cancer by 40 companies/universities/institutes. The top development phase for Adrenal Gland Cancer is phase ii with 25 drugs in that stage. The Adrenal Gland Cancer pipeline has 42 drugs in development by companies and five by universities/ institutes. Some of the companies in the Adrenal Gland Cancer pipeline products market are: Bristol-Myers Squibb, Eisai and Merck.
The key targets in the Adrenal Gland Cancer pipeline products market include Vascular Endothelial Growth Factor Receptor 2, Vascular Endothelial Growth Factor Receptor, and Mast/Stem Cell Growth Factor Receptor Kit.
The key mechanisms of action in the Adrenal Gland Cancer pipeline product include Vascular Endothelial Growth Factor Receptor Inhibitor with five drugs in Phase II. The Adrenal Gland Cancer pipeline products include 11 routes of administration with the top ROA being Intravenous and ten key molecule types in the Adrenal Gland Cancer pipeline products market including Small Molecule, and Monoclonal Antibody.
Adrenal Gland Cancer overview
Adrenal gland cancer is a rare type of neuroendocrine tumor that originates from the cells of the adrenal glands, which are located on top of the kidneys. The adrenal glands produce hormones that regulate various functions in the body, such as blood pressure, metabolism, stress response, and sex drive. Adrenal gland cancer can affect the production of these hormones, causing symptoms such as weight gain, muscle weakness, high blood pressure, hair growth, and mood changes. Adrenal gland cancer can be benign or malignant. The most common malignant adrenal gland cancer is adrenocortical carcinoma, which starts in the outer layer of the adrenal glands. Adrenal gland cancer can be diagnosed with blood tests, urine tests, imaging tests, and biopsy. Treatment options include surgery, radiation therapy, chemotherapy, and targeted therapy.
For a complete picture of Adrenal Gland Cancer’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
